Beilu Pharmaceutical: It is expected that the net profit will increase by 537.28%-852.26% year-on-year by 2025.

Northern Land Pharmaceutical announced that it is expected to achieve a net profit of 87 million to 130 million yuan in 2025, a year-on-year increase of 537.28% to 852.26%. After deducting non-recurring gains and losses, the net profit is expected to be 33 million to 49.5 million yuan, a year-on-year increase of 134.14% to 251.20%. During the reporting period, the company adhered to the dual-drive strategy of "chemical drugs + traditional Chinese medicine", deepened its presence in domestic and overseas markets, and achieved continued growth in revenue from chemical drug formulations, traditional Chinese medicine, and raw material drug products. The company continued to deepen its fine control measures such as reducing costs and increasing efficiency, steadily improving operational management efficiency, and significantly improving its performance. In August 2025, the "Northern Land Convertible Bonds" were redeemed and delisted, significantly reducing financial expenses compared to 2024. Additionally, the fair value of equity investments in associated companies increased. Multiple factors resonated to drive an increase in the net profit attributable to shareholders of the listed company during the reporting period compared to the same period last year.